. Author manuscript; available in PMC: 2017 Sep 6.

Published in final edited form as: Oncology. 2015 Jun 3;89(4):205–214. doi: 10.1159/000381917

Table 4.

Treatment outcomes

Survival - Entire cohort (N=119)

Subgroups	mTTP (months)		mOS (months)
Entire Cohort			12.1
First line	3.5
Second line	3.7
Third line	2.7

Type of chemotherapy	First line
Anthracycline-based	3.4	p=0.48	12.0	p=0.193
Taxane-based	3.6		11.6
Other	3.0		17.8
T or A single-agent	3.5	p=0.498	11.3	p=0.463
T or A combination	3.7		12.3

Site
Cutaneous	3.6	p=0.791	15.3	P=0.498
Non-cutaneous	3.0		10.9

Response to treatment – Evaluable patients (N=48)

Line of treatment	ORR (CR + PR)		SD
1^st (n=47)	30% (n=14)		40%(n=19)
2^nd (n=24)	8% (n=2)		42% (n=10)
3^rd (n=11)	9% (n=1)		27% (n=3)

Type of chemotherapy	ORR - First line
Anthracycline-based (n=20)	30% (n=6)		p=1.00
Taxane-based (n=13)	31% (n=4)
T or A single-agent (n=26)	27% (n=7)		p=0.726
T or A combination (n=7)	43% (n=3)

Site	ORR – First line
Cutaneous (n=8)	50% (n=4)		p=0.196
Non-cutaneous (n=38)	24% (n=9)

Abbreviations: Lipo-doxo – liposomal doxorubicin; ORR – overall response rate; CR – complete response; PR – partial response; SD – stable disease; T – taxane; A - anthracycline